TFR 4 OHT, also known as 4-Hydroxy-Tamoxifen, is a selective estrogen receptor modulator (SERM) primarily used in the treatment of hormone receptor-positive breast cancer. It is a derivative of tamoxifen and exhibits both estrogenic and anti-estrogenic properties, depending on the target tissue. The compound functions by binding to estrogen receptors, thereby inhibiting the proliferative effects of estrogen on breast tissue, which is crucial in the management of certain breast cancers. TFR 4 OHT is characterized by its ability to modulate gene expression and influence cell growth pathways. Its pharmacokinetics include oral bioavailability and metabolism primarily through the liver, leading to various metabolites that may also contribute to its therapeutic effects. Safety and efficacy profiles are well-studied, with common side effects including hot flashes, nausea, and potential thromboembolic events. As with any therapeutic agent, its use should be guided by clinical considerations and individual patient factors.

TFR4OHT is a cyclized tamoxifen analog. It acts as a selective ER modulator (SERM).

TFR 4 OHT

113748-88-2: TFR 4 OHT, also known as 4-Hydroxy-Tamoxifen, is a selective estrogen receptor modulator (SERM) primarily used in the treatment of hormone receptor-positive breast cancer. It is a derivative of tamoxifen and exhibits both estrogenic and anti-estrogenic properties, depending on the target tissue. The compound functions by binding to estrogen receptors, thereby inhibiting the proliferative effects of estrogen on breast tissue, which is crucial in the management of certain breast cancers. TFR 4 OHT is characterized by its ability to modulate gene expression and influence cell growth pathways. Its pharmacokinetics include oral bioavailability and metabolism primarily through the liver, leading to various metabolites that may also contribute to its therapeutic effects. Safety and efficacy profiles are well-studied, with common side effects including hot flashes, nausea, and potential thromboembolic events. As with any therapeutic agent, its use should be guided by clinical considerations and individual patient factors.

TFR4OHT is a selective ER modulator (SERM).

CAS 113748-88-2

TFR 4 OHT

TFR4OHT

Ref: TM-T28957